Cargando…

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluoro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, C. L., McKinna, F. E., Williams, L. B., Morrey, D., Adams, M., Mason, M. D., Maughan, T. S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033907/
https://www.ncbi.nlm.nih.gov/pubmed/7669593
_version_ 1782136939926781952
author Hanna, C. L.
McKinna, F. E.
Williams, L. B.
Morrey, D.
Adams, M.
Mason, M. D.
Maughan, T. S.
author_facet Hanna, C. L.
McKinna, F. E.
Williams, L. B.
Morrey, D.
Adams, M.
Mason, M. D.
Maughan, T. S.
author_sort Hanna, C. L.
collection PubMed
description We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 600 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment.
format Text
id pubmed-2033907
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20339072009-09-10 High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. Hanna, C. L. McKinna, F. E. Williams, L. B. Morrey, D. Adams, M. Mason, M. D. Maughan, T. S. Br J Cancer Research Article We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 600 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment. Nature Publishing Group 1995-09 /pmc/articles/PMC2033907/ /pubmed/7669593 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hanna, C. L.
McKinna, F. E.
Williams, L. B.
Morrey, D.
Adams, M.
Mason, M. D.
Maughan, T. S.
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title_full High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title_fullStr High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title_full_unstemmed High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title_short High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
title_sort high-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033907/
https://www.ncbi.nlm.nih.gov/pubmed/7669593
work_keys_str_mv AT hannacl highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT mckinnafe highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT williamslb highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT morreyd highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT adamsm highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT masonmd highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients
AT maughants highdosefolinicacidand5fluorouracilbolusandcontinuousinfusioninadvancedcolorectalcancerpoorresponserateinunselectedpatients